A5072521541- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Palliative Care and End-of-Life Issues
- Cancer Treatment and Pharmacology
- Nonmelanoma Skin Cancer Studies
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Neuroendocrine Tumor Research Advances
- Cancer Mechanisms and Therapy
- Cancer and Skin Lesions
- Hedgehog Signaling Pathway Studies
- Occupational and environmental lung diseases
- Multiple and Secondary Primary Cancers
- Ocular Oncology and Treatments
- Cutaneous lymphoproliferative disorders research
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
Azienda USL di Bologna
2020-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2015-2024
Policlinico S.Orsola-Malpighi
2013-2023
University of Bologna
2001-2023
Medica (Italy)
2020
Ospedale Papa Giovanni XXIII
2018
Azienda Ospedaliero Universitario Mater Domini
2018
Istituto Oncologico Veneto
2016
Mario Negri Sud Foundation
2015
Otsuka (Germany)
2015
The WHO guidelines on cancer pain management recommend a sequential three-step analgesic ladder. However, conclusive data are lacking as to whether moderate should be treated with either step II weak opioids or low-dose III strong opioids.In multicenter, 28-day, open-label randomized controlled study, adults were assigned receive opioid morphine. primary outcome was the number of responder patients, defined patients 20% reduction in intensity numerical rating scale.A total 240 (118 morphine...
In ADAURA, adjuvant osimertinib significantly improved disease-free survival versus placebo in resected stage IB to IIIA EGFR-mutated NSCLC. We report in-depth analyses of three-year safety, tolerability, and health-related quality life (HRQoL) from ADAURA.Patients were randomized 1:1 80 mg or once daily for up 3 years. Safety assessments performed at baseline, week 2, 4, 12, every 12 weeks until treatment completion discontinuation, 28 days after was stopped. The SF-36 survey measured HRQoL...
Background: To compare quality of life (QoL) patients receiving early palliative care (EPC) vs. standard oncologic (SOC). Methods: Pragmatic, multicenter, randomized trial at five University and Community Hospital Cancer Centers in Northern Italy. Advanced non-small cell lung, gastric, pancreatic biliary tract cancer diagnosed within the previous 8 weeks. In EPC arm, visits were performed systematically by a dedicated physician/nurse (PC) team, who assessed physical psychosocial symptoms,...
Ipilimumab is an immunomodulatory antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which administered to patients with advanced melanoma, a proven positive effect on overall survival. The cutaneous adverse effects (AEs) of ipilimumab are relatively frequent, although described as usually mild and rarely life threatening. To describe three-year experience single institute in detecting managing AEs. A cohort (n = 41) treated (3 mg/kg/three weeks) for metastatic...
Targeted therapies for melanoma have shown clinical benefit in increasing the survival of metastatic patients. Cutaneous adverse events been reported, but hair and nail data rarely detailed. Patients treated with BRAF MEK inhibitors underwent dermatological evaluation before start each treatment after every four weeks. Pull test, global photography, dermoscopy/trichoscopy scalp biopsy were performed. Appendages graded using National Cancer Institute's Common Terminology Criteria. Of 24...
To assess prognostic value of pre-therapy carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) blood levels in non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors (ICIs) their early change as predictor benefit.This is a retrospective cohort study including stage IIIB-IV NSCLC who received anti PD-1/PD-L1 first or advanced lines therapy two institutions. A control only chemotherapy has been enrolled well.A total 133 nivolumab atezolizumab...
Background/objectives: Despite advancements in early diagnosis and clinical practices guided by standardized care protocols, Merkel cell carcinoma (MCC) is still marked an unfavorable prognosis with a 5-year relative survival rate of 65%. Indeed, regional nodal metastases affect 40-50% MCC patients, while approximately 33% experience distant dissemination. Among these, bone marrow are particularly notable, although the characteristics implications this metastatic disease remain poorly...
Malignant acral melanoma (AM) is relatively infrequent in white patients. Molecular investigations have returned variable results regarding the mutational pattern. We sought to describe mutation profile and clinicopathologic features of AM.We investigated BRAF, KIT, NRAS status a series 31 AM samples from patients.Nodular was most common histopathologic subtype (48.4%), followed by lentiginous (25.8%) superficial spreading (25.8%). rates were 12.9%, 17.2%, 30.0%, respectively. observed...